Next, our data demonstrated that exogenous gp96 aggravated liver injury and inflammation, whereas targeting extracellular gp96 with its specific inhibitor pronouncedly attenuated the symptoms of LPS/d-Galn- or ConA-induced hepatitis and liver failure. The gene discussed is HSP90B1; the disease is Hepatic failure.